BOEHRINGER-INGELHEIM
13.1.2021 10:03:25 CET | Business Wire | Press release
Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard® COMBO topical solution for cats. This innovative parasiticide will be available in the European Union shortly. NexGard® COMBO offers unparalleled protection for cats: It kills a broader range of parasites than any other isoxazoline-based cat parasiticide currently available on the market.
As such, NexGard® COMBO eliminates fleas, ticks, and ear mites, prevents heartworm disease and treats hookworm, roundworm, vesical worm, lungworm, as well as tapeworm infections. Active ingredients are esafoxolaner (the new generation of afoxolaner), eprinomectin, and praziquantel.
Infection by both external and internal parasites is common in cats and occurs at a significant rate worldwide.1,2 NexGard® COMBO provides efficacy against both types of parasites with a triple action formula – making compliance to treatment recommendations easier for cat owners. Application is also easy for cat owners with the syringe-shaped pipette.
Multiple clinical studies supported the approval and showed that NexGard® COMBO:
- Kills fleas before they can lay eggs and maintains efficacy for one month3
- Kills the most common tick species in cats: Ixodes scapularis for one month and Ixodes ricinus for five weeks3
- Is 100 percent effective in preventing heartworm disease4
- Is 100 percent effective against Echinococcus multilocularis 4
- Exceeds the 90 percent regulatory threshold for other internal parasite efficacy4
- Is safe for cats and kittens as young as 8 weeks and weighing at least 0.8kg3
“Boehringer Ingelheim has always been on the cutting edge of research and development in the parasiticide space, and we’re thrilled to continue that pioneering approach with the granting of a marketing authorization for NexGard® COMBO for cats in the EU. NexGard® COMBO is the first isoxazoline-based full endectocide developed specifically for cats,” shares Dr. Craig Beck, Global Franchise Head NexGard® , Boehringer Ingelheim Animal Health. “We’re dedicated to being the global leader in feline health care and the launch of NexGard® COMBO for cats expands our trusted feline product portfolio.”
The NexGard® family of products is the global #1 pet parasiticides brand in sales5 and has been used worldwide over 465 million times in dogs6 . Now, for the first time, the brand has expanded to feline parasite control products.
Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/nexgard-combo-cats-ema-marketing-authorization
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005334/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom